The announcement was made after KT Rama Rao’s meeting with the Managing Director and Chief Executive Officer of Gland Pharma Srinivas Sadu.
(From left) Jayesh Ranjan Principal Secretary, Industries and Commerce Department, Telangana IT and Industries Minister KT Rama Rao, Gland Pharma CEO Srinivas Sadu, and Shakthi M Nagappan, CEO of Telangana Lifesciences during a meeting to discuss Genome Valley investment. (KTR/BRSTwitter)
Gland Pharma has announced an investment of over ₹400 crore in Genome Valley in Hyderabad to include additional capabilities to their existing facility of manufacturing biologicals, biosimilars, antibodies and recombinant insulin.
The expanded facility will have employment generation potential of more than 500 qualified, skilled, and semi-skilled workforce, mostly from nearby places.
Founded in 1978, the company established its biopharmaceutical facility at Genome Valley in February 2022 with an investment of ₹300 crore to manufacture vaccines, biologicals, biosimilars, and antibodies, among other things.
The recruitment of 200 persons has already been completed in the facility.
The expanded site is expected to meet the regulations — national and international — to be followed in the manufacturing of the biological products, as applicable, and shall be built under the GMP guidelines applicable for the respective product lines.
The announcement was made after Telangana Industries Minister KT Rama Rao’s meeting with the Managing Director and Chief Executive Officer of Gland Pharma Srinivas Sadu.
Industries and Commerce Department Principal Secretary Jayesh Ranjan and Telangana Lifesciences CEO Shakthi M Nagappan were also present at the meeting.
KT Rama Rao said about the investment that he was “excited that the expansion will be focused on advanced areas like biologicals, biosimilars, antibodies, and recombinant insulin, all of which are areas where the state is focused on building capabilities and consolidating our leadership position”.
Gland Pharma Limited is a generic injectable-focused pharmaceutical company that has been making healthcare products for more than 40 years.
Currently, it operates eight manufacturing facilities in India, with a finished formulation capacity of approximately 1,000 million units.
These include four facilities with 28 production lines for finished formulations and four Active Pharmaceutical Ingredient (API) facilities, including the Genome Valley facility for biopharmaceutical Drug Substance (DS).
Delighted to announce that @glandpharma is expanding their footprint in Genome Valley by investing ₹ 400 crores and creating 500 more jobs for advance areas such as biologicals
Strength of @TS_LifeSciences and Genome Valley is only growing everyday!#TelanganaleadsLifeSciences pic.twitter.com/54EFLphQcO
— KTR (@KTRBRS) February 20, 2023
Genome Valley is India’s first organised cluster for life sciences R&D and clean manufacturing activities, with world-class infrastructure in the form of industrial and knowledge parks, Special Economic Zones (SEZs), multi-tenanted dry and wet laboratories and incubation facilities.
It is home to more than 200 companies — with a scientific workforce of about 15,000 professionals.
The companies include marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, and Lonza.
May 19, 2024
May 19, 2024
May 19, 2024
May 19, 2024
May 19, 2024
May 18, 2024
